Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy-Application of A New Multivariate Predictive Model. The Life Study.
aortic root diameter
blood pressure
hypertension
left ventricular hypertrophy
Journal
Reviews in cardiovascular medicine
ISSN: 1530-6550
Titre abrégé: Rev Cardiovasc Med
Pays: Singapore
ID NLM: 100960007
Informations de publication
Date de publication:
10 Mar 2022
10 Mar 2022
Historique:
received:
17
12
2021
revised:
31
12
2021
accepted:
11
01
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
19
4
2022
Statut:
ppublish
Résumé
Available nomograms to predict aortic root (AoR) diameter for body surface area have limitations. The purpose of this study was to evaluate the use of a new multivariate predictive model to identify AoR dilatation in hypertensive patients with left ventricular hypertrophy. 943 of 961 patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiographic sub-study had the necessary baseline characteristics and echocardiographic 2D measurements of AoR size to be included. Predicted AoR (Sinus of Valsalva) diameter was 1.519 + (age [years] × 0.010) + (height [cm] × 0.010) - (gender [1 = M, 2 = F] × 0.247), and a measured AoR diameter exceeding the 97.5-percentile of this estimate was considered dilated. Measured AoR diameter was larger in men than in women (3.75 vs. 3.48 cm, Using the proposed model the prevalence of AoR dilatation was equal in men and women and the model seems to address the effects of gender, age and body size on AoR size. URL: https://www. gov; Unique identifier: NCT00338260.
Sections du résumé
BACKGROUND
BACKGROUND
Available nomograms to predict aortic root (AoR) diameter for body surface area have limitations. The purpose of this study was to evaluate the use of a new multivariate predictive model to identify AoR dilatation in hypertensive patients with left ventricular hypertrophy.
METHODS
METHODS
943 of 961 patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiographic sub-study had the necessary baseline characteristics and echocardiographic 2D measurements of AoR size to be included.
RESULTS
RESULTS
Predicted AoR (Sinus of Valsalva) diameter was 1.519 + (age [years] × 0.010) + (height [cm] × 0.010) - (gender [1 = M, 2 = F] × 0.247), and a measured AoR diameter exceeding the 97.5-percentile of this estimate was considered dilated. Measured AoR diameter was larger in men than in women (3.75 vs. 3.48 cm,
CONCLUSIONS
CONCLUSIONS
Using the proposed model the prevalence of AoR dilatation was equal in men and women and the model seems to address the effects of gender, age and body size on AoR size.
CLINICAL TRIAL REGISTRATION
BACKGROUND
URL: https://www.
CLINICALTRIALS
RESULTS
gov; Unique identifier: NCT00338260.
Identifiants
pubmed: 35345262
pii: S1530-6550(22)00418-5
doi: 10.31083/j.rcm2303095
doi:
Banques de données
ClinicalTrials.gov
['NCT00338260']
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
95Informations de copyright
© 2022 The Author(s). Published by IMR Press.
Déclaration de conflit d'intérêts
Sverre E. Kjeldsen has received lecture honoraria within the past 3 years from Getz Pharma, Merck Healthcare KGaA, Sanofi-Aventis and Vector-Intas. The other authors declare that they have no conflicts of interest.